BAYER Schering has signed a
deal with EndoCeutics for the
development and commercialisation
of a new intra-vaginal medication
for the treatment of vaginal atrophy
and female sexual dysfunction in
postmenopausal women.
According to Bayer, Vaginorm
(dehydroepiandrosterone or DHEA),
which is currently in its phase III
trials, is set to meet a “largely
unmet medical need” in treating
women who experience changes to
their vaginal tissue after
menopause, with reports showing
almost 25% of all post menopausal
women suffer from one form or
another of vaginal atrophy.The above article was sent to subscribers in Pharmacy Daily's issue from 06 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 May 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.